Oxford BioMedica is recruiting artificial intelligence to improve the productivity, purity, and manufacturing of viral vectors used in its gene therapies, which target diseases such as cancer and age-related macular degeneration. The company has signed a two-year development collaboration with Microsoft to access its artificial intelligence platform, called Station B.